Net Product Revenues was Pelthos Therapeutics’s largest product and service line in fiscal 2025, bringing in $16.21M of $16.80M (96%).
| Product and Service | FY 2025 |
|---|---|
| Net Product Revenues | $16.21M |
| License & Collaboration Revenues | $589.00K |
| Total | $16.80M |
Pelthos Therapeutics brought in $16.80M from its two product and service lines in fiscal 2025, the year ended December 31, 2025. Net Product Revenues was the largest at $16.21M (96.5%), ahead of License & Collaboration Revenues at $589.00K (3.5%).
Commercial Operations was Pelthos Therapeutics’s largest segment in fiscal 2025, bringing in $16.21M of $16.80M (96%).
| Segment | FY 2025 |
|---|---|
| Commercial Operations | $16.21M |
| Research & Development Operations | $589.00K |
| Total | $16.80M |
Pelthos Therapeutics brought in $16.80M from its two segments in fiscal 2025, the year ended December 31, 2025. Commercial Operations was the largest at $16.21M (96.5%), ahead of Research & Development Operations at $589.00K (3.5%).
Pelthos Therapeutics (PTHS) reports its revenue by product and service and by segment. In fiscal 2025, Net Product Revenues was its largest product and service line, bringing in $16.21M (96.5% of the total), followed by License & Collaboration Revenues at $589.00K (3.5%).
Net Product Revenues was Pelthos Therapeutics' largest product and service line in fiscal 2025, bringing in $16.21M, or 96.5% of the $16.80M total across its two product and service lines.
Commercial Operations was Pelthos Therapeutics' largest segment in fiscal 2025, bringing in $16.21M, or 96.5% of the $16.80M total across its two segments.
Every figure comes from Pelthos Therapeutics' annual financial filings, as reported. Each line keeps the name Pelthos Therapeutics gives it, and years follow its fiscal calendar.
Pelthos Therapeutics' revenue by product and service goes back to fiscal 2025, with figures through fiscal 2025. The latest four fiscal years are free to view, and the full history is available with a Business Quant subscription.